Why the study?
The study was conducted to evaluate the pharmacokinetic parameters of Angipur, a novel nonpeptide glycoprotein IIb/IIIa receptor inhibitor, after single-dose ascending infusions in healthy volunteers.
The novel nonpeptide glycoprotein IIb/IIIa receptor inhibitor Angipur exhibits linear pharmacokinetics and rapid peak plasma concentrations in healthy volunteers, supporting its further clinical development.
Answers are grounded in this paper and cite their sources.
Establishes first PK profile for novel nonpeptide GP IIb/IIIa inhibitor; leaves open clinical role pending patient efficacy and safety trials.
Relevance. As part of the conducted open non-randomized phase I clinical trial the pharmacokinetics (PK) of the first Russian novel antiplatelet agent Angipur (nonpeptide glycoprotein IIb/IIIa receptor inhibitor) was studied. Aim of the research was to evaluate PK parameters of Angipur in healthy volunteers after single dose ascending infusions. Methods. 20 male healthy volunteers were enrolled in this phase I trial. Angipur (0.02% concentrate solution for infusion) was administered to every subject in single doses 0.015, 0.05, 0.09 mg/kg for 3 consecutive days. PK parameters were evaluated. Results. After single intravenous administration of doses 0.015, 0.05, 0.09 mg/kg to healthy volunteers the peak plasma concentration of Angipur was reached at the end of the infusion, and then the plasma concentration rapidly decreased 15 minutes after the end of the infusion followed by slow decrease for 12 hours. Dose proportionality for key PK parameters was established. After single infusions of doses 0.015, 0.05, 0.09 mg/kg mean AUC 0-t was 27.11, 92.04 and 180.39 ng× h/ml; mean AUC 0- ¥ – 37.03, 125.76 and 239.61 ng×h/ml; mean С max – 12.44, 46.1 and 92.48 ng/ml; mean V d – 304.01, 299.67 and 252.96 l; mean Т 1/2 – 6.72, 6.84 and 6.06 h; Сl – 32.19, 32.29 and 31.55 l/h; k el – 0.1073, 0.1109 and 0.1257 l/h; MRT – 8.94, 8.93 and 8.18 h. Conclusion. Pharmacokinetics of Angipur in studied doses demonstrated linearity, rapid reaching of С max immediately after the infusion and the high distribution of the drug in tissues and biological fluids of the human organism..
No takes yet. Share an insight, caveat, or question.
Фитилев et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: